Zumutor Biologics is a biopharma company that develops biobetters, new biological entities and biosimilars to large antibody structures.
Zumutor creates product portfolios focused on immuno-oncology. The Company's interest lies in oncology, diabetes and autoimmune disorders.
Zumutor was founded in India in 2015 by Kavitha Iyer Rodrigues. The company is based in Woburn, Massachusetts, and Bangalore, India.
Zumutor Biologics has two proprietary Antibody Engineering Platforms to develop novel immunotherapies that target innate immunity and regulate the tumor microenvironment.
Zumutor engage in cutting edge research and development with proprietary antibody engineering platforms to develop novel combinatorial immuno-oncotherapeutics that target innate immunity and regulation of the Tumour Micro environment.
Zumutor’s ZM008 is a first-in-class antibody molecule that it says activates the natural killer (NK) cells in a patient’s body to fight off the cancer cells. It has created these molecules through its proprietary antibody discovery platform, INABLR.
Zumutor is backed by Accel Partners, Bharat Innovation Fund, Chiratae Ventures, IDG Ventures SEA, Siana Capital, and others. The company raised $6.2M in new financing on Dec 09, 2021. This brings Zumutor's total funding to $26.2M to date.